DaVita Q3 2026: adjusted EPS beats, GAAP misses on China charge
DaVita's third quarter of 2026 beat the number investors watch and missed the one accountants count: adjusted EPS of $3.82 cleared the $3.64 consensus, while GAAP EPS of $3.40 did not, because a $62 million China impairment ran through operating income. Revenue rose 4.6% to $3.58 billion. Read it as a steady core with thinning margins and weaker cash conversion.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS of $3.40 came in $0.24 below the $3.64 consensus, dragged by a $62 million non-cash China impairment worth about $0.41 a share after the minority-interest and tax offsets. Adjusted EPS of $3.82 beat by $0.18. Net income attributable to DaVita was $222.9 million against $150.3 million a year ago, though that prior-year figure was itself depressed.
Revenue of $3.58 billion rose 4.6% from $3.42 billion a year earlier. Volume barely moved: normalized non-acquired treatment growth was 0.4%, so most of the increase came from pricing and payor mix rather than more patients. Revenue per treatment actually slipped $0.62 sequentially to $415.25.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.